Phase II Trial of Remitogen™ (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma-Reference-Cited by-同舟云学术

Phase II Trial of Remitogen™ (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma

Published:2001-12 Issue:3 Volume:2 Page:188-190
ISSN:1526-9655
Container-title:Clinical Lymphoma
language:en
Short-container-title:Clinical Lymphoma

Author:

Brown Kevin S.,Levitt Daniel J.,Shannon Mary,Link Brian K.

Publisher

Elsevier BV

Subject

Cancer Research

Reference10 articles.

1. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma;Maloney;Blood,1997

2. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study;Coiffier;Blood,1998

3. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial;Coiffier;Blood,2000

4. Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes;Gingrich;Blood,1990

5. Growth inhibition of Epstein-Barr virus-transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down-regulation of CD23 antigen expression;Kabelitz;Cell Immunol,1989

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I Study of Apolizumab, an Anti-HLA-DR ß-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies;American Journal of Clinical Oncology;2022-06-01

2. B cell MHC class II signaling: A story of life and death;Human Immunology;2019-01

3. Update on Chronic Lymphocytic Leukemia: Overview of New Agents and Comparative Analysis;Current Treatment Options in Oncology;2013-03-15

4. Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study;Cancer Immunology, Immunotherapy;2012-10-23

5. SCIMP, a Transmembrane Adaptor Protein Involved in Major Histocompatibility Complex Class II Signaling;Molecular and Cellular Biology;2011-11-15